GTx, Inc. (Nasdaq: GTXI) today provided a company update and reported financial results for the first quarter of 2011.
“We have made strong progress in both the Ostarine and Capesaris clinical development programs”
“We have made strong progress in both the Ostarine and Capesaris clinical development programs,” said Mitchell S. Steiner, MD, CEO of GTx. “The indication we will pursue for Ostarine is the prevention and treatment of muscle wasting in patients with non-small cell lung cancer. We expect to initiate two pivotal Phase III clinical trials in the third quarter.”
